BMI

Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Retrieved on: 
Monday, January 22, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Senior, Roger Hawkins (drummer), Tamas, Patient, Carcinoma, MD, ADC, OS, UC, Bladder cancer, Brentuximab vedotin, ASCO, CUP, Survival, Society, READY, Quality of life, Experiment (probability theory), Safety, PRO, Toxicity, Doctor of Philosophy, BMI, Physical property, BSC, Czech, Pharmaceutical industry

Data include real-world studies that confirm median overall survival (OS) of approximately 30 months in patients without progression after first-line chemotherapy.

Key Points: 
  • Data include real-world studies that confirm median overall survival (OS) of approximately 30 months in patients without progression after first-line chemotherapy.
  • These and other analyses will be presented at the 2024 American Society of Clinical Oncology’s annual Genitourinary Cancers Symposium, January 25-27, in San Francisco.
  • “Avelumab in the first-line maintenance setting is a standard of care for patients with locally advanced or metastatic bladder cancer, with a well-established efficacy and safety profile and supported by years of real-world experience.
  • READY CUP Italy Real-World Study: The prospective, noninterventional compassionate use program (CUP) provided Italian patients with locally advanced or metastatic UC early access to BAVENCIO first-line maintenance before reimbursement.

US Stocks Scored Big Wins In 2023, Per Beatmarket Oy, Who Sees The Success Story Marching Into 2024

Retrieved on: 
Friday, January 26, 2024
Magnificent Seven, Magnificent, FAANG, Leg, Federal Reserve, Rejuvenation, AMD, Fed, BMI, GDP, Nvidia, Growth

Investors forgot they ever doubted the Fed and whipped out the Champagne when Jerome Powell promised to get the party started again in 2024.

Key Points: 
  • Investors forgot they ever doubted the Fed and whipped out the Champagne when Jerome Powell promised to get the party started again in 2024.
  • The Magnificent Seven megacaps contributed nearly half of overall market upside, reviving the Nasdaq from its pandemic lows.
  • Contrary to expert predictions, the US stock market witnessed an outstanding performance throughout 2023 and speeds up in January 2024.
  • Through comprehensive reports grounded in data and rigorous analysis, we aim to provide clients the insights needed to make well-informed investment decisions."

Brad Gilbert, 21-Year Veteran of BMI Imaging, Named Executive Vice President

Retrieved on: 
Wednesday, January 24, 2024
Software, BMI, Brad Gilbert, Library, Creativity, Executive, Growth, Management

SUNNYVALE, Calif., Jan. 24, 2024 /PRNewswire-PRWeb/ -- BMI, a leader in digitization and records management, is proud to announce the promotion of Brad Gilbert, a long-time key member of the BMI team, to the position of Executive Vice President. This promotion comes as a testament to his remarkable contributions to the company since joining in 2002.

Key Points: 
  • BMI is proud to announce that Brad Gilbert, long-time employee and Head of Software, has been named Executive Vice President.
  • SUNNYVALE, Calif., Jan. 24, 2024 /PRNewswire-PRWeb/ -- BMI, a leader in digitization and records management, is proud to announce the promotion of Brad Gilbert, a long-time key member of the BMI team, to the position of Executive Vice President.
  • In addition to his technical expertise, Brad is an accomplished leader, effectively managing the software, IT, and finance departments at BMI.
  • We're excited to see him take on this new role and lead BMI into a promising future," said Will Whitney, CEO of BMI.

Pandia Health Expands its Hormonal Services to Mid-Life Women with Menopause Care

Retrieved on: 
Wednesday, January 17, 2024
Health care, Woman, Stanford University, Patient, Multimedia, Insurance, Genetics, Private practice, Bible, Prescription, Menopause, Growth, Q&A, FACOG, MSCP, BMI, Open enrollment, Internet, MPH, Acne, Triage, NPS, Birth control

SUNNYVALE, Calif., Jan. 17, 2024 /PRNewswire/ -- Pandia Health, the only women-founded and women-led company providing customized birth control treatment and delivery, which expanded its services into acne treatment last year, announced today its expansion into hormonal treatment for menopause. The company also announced today its new Chief Executive Officer, Alice Eweida, who previously led growth and brand marketing at several Series B digital health companies, including Boulder Care and DayTwo.

Key Points: 
  • Pandia Health's menopause services are led by two of the approximately 1,000 MSCP-certified practitioners in the US.
  • Pandia Health is additionally offering its menopause services to employers with annual Q&A sessions for employees during Open Enrollment, two virtual education sessions with Pandia Health's hormonal experts, and more.
  • Founded in 2016, Pandia Health, the only women-founded and women-led birth control delivery company, is building the online health brand women trust.
  • By providing online doctors' visits for prescriptions and medication delivery, Pandia Health empowers women with convenient, confidential, and reliable access to expert women's hormonal care.

WeightWatchers Unveils “Beyond Hunger: Understanding Food Noise” Report Offering Insights Into the Experience of Ongoing, Intrusive Thoughts About Food

Retrieved on: 
Tuesday, January 16, 2024
Obesity, Family, George Washington, Learning, MD, Food, Weight loss, Partnership, Friends, George Washington University, Wellness, Quality of life, Social stigma of obesity, Empathy, WW International, BMI, Doctor of Philosophy, Overweight, Fast food

“The difference between food noise being problematic or not comes down to how often and how intensely it’s occurring.

Key Points: 
  • “The difference between food noise being problematic or not comes down to how often and how intensely it’s occurring.
  • Food noise that occurs daily can be so intense and intrusive that it negatively impacts food choices and quality of life,” said Dr. Spencer Nadolsky, obesity and lipid specialist physician and medical director, WeightWatchers.
  • “With constant, intrusive thoughts about food, it’s difficult to navigate behavioral change without clinical help.
  • Yet, because of the depth of weight-related stigma, food noise is often ignored as a contributing factor to obesity.

New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease

Retrieved on: 
Wednesday, January 10, 2024
Diabetes, RWE, American Heart Association, Patient, Diabetic nephropathy, Kidney, MD, Hypertension, Risk assessment, Type 2 diabetes, Insurance, Heart failure, Risk, Food, Chronic kidney disease, Real world evidence, CKD, Community health, FDA, Doctor of Philosophy, BMI, Real, EGFR, Marketing, Physician, Pharmaceutical industry

LONDON and SALT LAKE CITY, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces publication of Real World Evidence (“RWE”) after 12 months of follow-up in 2,569 patients with Type 2 diabetes and diabetic kidney disease (“DKD”) at a major U.S. health system in Primary Care and Community Health. Results in the diverse cohort, including 27% black patients, demonstrate that electronic health record deployment of KidneyIntelX in vitro prognostic testing was associated with clinical actions that led to a significant slowing of chronic kidney disease progression and improved Type 2 diabetes control most notably in the highest risk patients.

Key Points: 
  • Improved kidney health was evidenced by reduction in the rate of kidney function decline (eGFR slope) and diabetes control was evidenced by improved A1C levels.
  • KidneyIntelX testing achieved scale through electronic health record integration, deploying directly to large treating groups of primary care physicians.
  • KidneyIntelX has received broad insurance payment coverage including through Medicare, Medicaid, and Blue Cross Blue Shield programs.
  • “The demonstrated benefits of KidneyIntelX early risk assessment at one year are significant and go to the core of chronic disease preventative medicine.

Pursuant Health Unveils FDA-Cleared Retinal Imaging Kiosk - a First in On-Demand Healthcare

Retrieved on: 
Friday, January 12, 2024
Diabetes, Research, Pulse, Health, Hypertension, Paratriathlon, Optic nerve, Public, Diabetic retinopathy, CDC, FDA, Common, BMI, Body mass index, Blood, Ageing, Blood pressure, Medical imaging

ATLANTA, Jan. 12, 2024 /PRNewswire/ -- Pursuant Health announced today a breakthrough in making a critical preventive care service more accessible to the American public. Pursuant Health's newest kiosk model, now equipped with state-of-the-art retinal imaging technology, has received 510(k) clearance from the U.S. Federal Drug Administration (FDA). This kiosk is the first to offer self-service retinal imaging, enabling individuals to capture their own images quickly and effortlessly.

Key Points: 
  • Pursuant Health's newest kiosk model, now equipped with state-of-the-art retinal imaging technology, has received 510(k) clearance from the U.S. Federal Drug Administration (FDA).
  • This kiosk is the first to offer self-service retinal imaging, enabling individuals to capture their own images quickly and effortlessly.
  • Leslie Sommers, CEO of Pursuant Health, emphasizes the kiosk's role in simplifying healthcare: "Our goal is to streamline healthcare for everyone involved.
  • Looking ahead, Pursuant Health aspires to leverage retinal imaging for broader health analysis.

HNRC Outlines Key Highlights Presentation for 2024

Retrieved on: 
Wednesday, January 10, 2024
Permian, CUSIP, Fitch Ratings, Kingdom, Placer, CNRC, Interest, Skeena, Silver, Cobalt, Mining, KCC, Gold, OTC, Acquisition, IPO, CML, Lithium, Copper, Cold Lake, BMI, Non, Engineering, LH

HOUSTON, Jan. 10, 2024 /PRNewswire/ -- Houston Natural Resources Corp (OTC: HNRC) ("HNRC or the Company") with a pending name, symbol and CUSIP change, to Cunningham Natural Resources Corp, outlined an investor presentation for 2024.

Key Points: 
  • HOUSTON, Jan. 10, 2024 /PRNewswire/ -- Houston Natural Resources Corp (OTC: HNRC) ("HNRC or the Company") with a pending name, symbol and CUSIP change, to Cunningham Natural Resources Corp, outlined an investor presentation for 2024.
  • Cunningham Energy and its affiliates own interests in approximately 600 wells, 170 of which are re-works with a 98% successful completion rate.
  • The company acquired 30,000 net acres in numerous transactions throughout the Appalachian Basin Acreage acquisition was completed over a 10-year time frame.
  • Based on the investment being made by HNRC, KCC would have an enterprise value of about US$60 million dollars.

BMI Mergers & Acquisitions Assists Ideametrics in Sale to Smart ERP Solutions, Inc.

Retrieved on: 
Wednesday, January 10, 2024
Cloud, ERP, Century, Oracle Cloud, JD Edwards, Partnership, HCM, EPM, Sale, Oracle, Acquisition, 3rd century, Organization, BMI, Mergers and acquisitions, PeopleSoft

CHARLOTTE, N.C., Jan. 10, 2024 /PRNewswire-PRWeb/ -- BMI Mergers & Acquisitions, a lower middle-market investment bank, announced the sale of its client, Ideametrics, a cloud consulting company to Smart ERP Solutions, Inc., a portfolio company of Third Century.

Key Points: 
  • BMI Mergers & Acquisitions, an investment bank, has announced the sale of its client Ideametrics, a cloud consulting company, to Smart ERP Solutions, a portfolio company of private equity firm Third Century.
  • Smart ERP Solutions, established in 2005, offers services to address common business challenges and has expertise with various Oracle ERP applications.
  • This deal highlights BMI Mergers & Acquisitions' strong capabilities in advising technology services companies in the middle market on M&A transactions.
  • CHARLOTTE, N.C., Jan. 10, 2024 /PRNewswire-PRWeb/ -- BMI Mergers & Acquisitions, a lower middle-market investment bank, announced the sale of its client, Ideametrics, a cloud consulting company to Smart ERP Solutions, Inc., a portfolio company of Third Century.

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024
Blood pressure, Patient, Medical Subject Headings, Marketing, European Commission, Agency, INN, Weight, Constipation, Risk, ATC, Weight loss, Blood, International, Diet, BMI, European, Diabetes, Method, Nausea, Language, Brain, Bupropion, Heart, Dizziness, Naltrexone, Body mass index, Appetite, Food, Kidney, Tablet, Interim, Xerostomia, Select, Human, Safety, Risk management, Anatomy, Medicine, Seizure, Pleasure, Vomiting, IIA, CHMP, Exercise, Medical device

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised